I. Poschke

发表

Tumor‐dependent down‐regulation of the ζ‐chain in T‐cells is detectable in early breast cancer and correlates with immune cell function

R. Kiessling, Y. Mao, J. Boniface, 2012, International journal of cancer.

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

J. Bergh, R. Kiessling, M. Piechocki, 2010, Journal of Translational Medicine.

The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

R. Offringa, J. Haanen, R. Kiessling, 2020, Clinical Cancer Research.

Higher Antioxidative Capacity Than the Produced by Activated Granulocytes and Has Resistant to Reactive Oxygen Species CD56bright NK Cell Subset Is - The CD16

R. Kiessling, D. Sakurai, H. Norell, 2013 .

The CD16 CD56 NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16 CD56 Subset

R. Kiessling, D. Sakurai, H. Norell, 2007 .

The CD16−CD56bright NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16+CD56dim Subset1

R. Kiessling, K. Malmberg, D. Sakurai, 2007, The Journal of Immunology.

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

B. Seliger, A. Moosmann, T. Blankenstein, 2008, Proceedings of the National Academy of Sciences.

Camouflage and sabotage: tumor escape from the immune system

D. Mougiakakos, R. Kiessling, I. Poschke, 2011, Cancer Immunology, Immunotherapy.

Tumor‐induced changes in the phenotype of blood‐derived and tumor‐associated T cells of early stage breast cancer patients

R. Kiessling, J. de Boniface, Y. Mao, 2012, International journal of cancer.

Cyclooxygenase-2

R. Kiessling, I. Poschke, Y. Mao, 2013 .

On the armament and appearances of human myeloid-derived suppressor cells.

R. Kiessling, I. Poschke, 2012, Clinical immunology.

Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation

R. Spang, M. Boutros, R. Offringa, 2022, Journal for ImmunoTherapy of Cancer.

Down-Regulating DNAM-1 on NK Cells CD 155 Impair Tumor Targeting by Primary Human Tumor Cells Expressing Kiessling and

H. Ljunggren, R. Kiessling, K. Malmberg, 2009 .

Down-regulating Dnam-1 on Nk Cells Cd155 Impair Tumor Targeting by Primary Human Tumor Cells Expressing

H. Ljunggren, R. Kiessling, K. Malmberg, 2022 .

T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2

B. Seliger, D. Mougiakakos, M. Nishimura, 2011, International journal of cancer.

Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients

R. Kiessling, J. de Boniface, I. Poschke, 2012, Oncoimmunology.

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

R. Kiessling, R. Tell, J. Hansson, 2020, Oncoimmunology.

Next‐generation TCR sequencing – a tool to understand T‐cell infiltration in human cancers

R. Offringa, Michael Flossdorf, I. Poschke, 2016, The Journal of pathology.

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

G. Reifenberger, G. Tabatabai, A. Wick, 2022, Neurological Research and Practice.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

R. Kiessling, Yuan Yang, J. Hansson, 2017, Oncotarget.

A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes

M. Boutros, R. König, R. Offringa, 2015, EMBO molecular medicine.

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation

D. Mougiakakos, R. Jitschin, P. Ljungman, 2013, Leukemia.

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

R. Kiessling, F. Salazar-Onfray, G. Masucci, 2012, Cancer Immunology, Immunotherapy.

Tumor-mediated changes in the immune system of cancer patients - a balancing act between suppressors and effectors

I. Poschke, 2011 .

Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.

F. Salazar-Onfray, A. Lundqvist, A. Achour, 2014, Immunobiology.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

D. Mougiakakos, R. Kiessling, J. Hansson, 2009, Cancer Immunology, Immunotherapy.

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis

B. Seliger, E. Andersson, R. Kiessling, 2015, Oncoimmunology.

A vaccine targeting mutant IDH1 in newly diagnosed glioma

S. Stevanović, I. Harting, S. Justesen, 2021, Nature.

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

N. Halama, A. Trumpp, M. Büchler, 2016, Oncoimmunology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

David T. W. Jones, C. Plass, I. Harting, 2020, BMC Cancer.

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

E. Andersson, R. Kiessling, R. Tell, 2014, Cancer Immunology, Immunotherapy.

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display

E. Reinherz, B. Seliger, R. Offringa, 2019, Front. Immunol..

Tumour‐induced immune suppression: role of inflammatory mediators released by myelomonocytic cells

R. Kiessling, I. Poschke, Y. Mao, 2014, Journal of internal medicine.

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

D. Mougiakakos, R. Kiessling, J. Hansson, 2010, Cancer research.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production

R. Kiessling, J. Hansson, G. Masucci, 2014, Journal of Translational Medicine.

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer

R. Kiessling, J. de Boniface, J. Boniface, 2016, Journal of Translational Medicine.

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

S. Dietrich, P. Dreger, H. Kräusslich, 2021, Blood.

The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

R. Kiessling, K. Malmberg, D. Sakurai, 2007, Journal of immunology.

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer

R. Kiessling, J. de Boniface, I. Poschke, 2016, Journal of Translational Medicine.

Miniatures Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase 1 Production

R. Kiessling, J. Hansson, G. Masucci, 2013 .

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

R. Kiessling, J. Hansson, I. Schultz, 2013, Cancer research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells

R. Offringa, M. D’Elios, R. Fischer, 2020, Science Signaling.

Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells

R. Offringa, M. D’Elios, R. Fischer, 2019, Science Signaling.

Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes

R. Kiessling, J. de Boniface, I. Poschke, 2013, Journal of Translational Medicine.

Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer

T. Giese, R. Offringa, J. Werner, 2014, Clinical Cancer Research.

Neoepitope-specific vaccination of a patient with diffuse midline glioma targeting H3K27M induces polyclonal B and T cell responses across diverse HLA alleles

John M. Lindner, Niklas Grassl, M. Plattén, 2023, bioRxiv.

Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10–11, 2007

R. Kiessling, S. Vertuani, C. Johansson, 2008, Cancer Immunology, Immunotherapy.

Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes

R. Kiessling, J. de Boniface, I. Poschke, 2013, Journal of Translational Medicine.

optiPRM: A targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material

S. Fröhling, A. Riemer, R. Offringa, 2023, bioRxiv.

8P Pre-treatment blood gene expression changes associated with durable clinical benefit in metastatic non-small cell lung cancer with high PD-L1 expression receiving first-line pembrolizumab

M. Kriegsmann, A. Stenzinger, M. Meister, 2021, Annals of Oncology.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production

R. Kiessling, J. Hansson, G. Masucci, 2013, Journal of Translational Medicine.

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

B. Seliger, A. Moosmann, T. Blankenstein, 2008, Proceedings of the National Academy of Sciences.

Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells1

H. Ljunggren, R. Kiessling, Y. Bryceson, 2009, The Journal of Immunology.